1445993-85-0

Basic information

• Product Name: 4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine
• Synonyms: 4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine
• CAS NO: 1445993-85-0
• Molecular Formula: C₁₅H₁₃BrN₂O₃S
• Molecular Weight: 381.24432
• Mol File: 1445993-85-0.mol
• Article Data: 31

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine(1445993-85-0)
• EPA Substance Registry System: 4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine(1445993-85-0)

Safety Data

• Hazardous Substances Data: 1445993-85-0(Hazardous Substances Data)

Usage

General Description

4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine is a chemical compound with the molecular formula C14H11BrN2O3S. It is a pyrrolopyridine derivative that contains a bromine atom, a methoxy group, and a tosyl group. 4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine is used in organic synthesis and medicinal chemistry as a building block for the synthesis of various biologically active molecules. Additionally, it has been studied for its potential pharmacological properties, particularly as a potential anti-cancer agent. The specific chemical structure and properties of 4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine make it an important compound in pharmaceutical research and drug discovery.

Upstream product

• 917918-81-1 2-(5-bromo-2-methoxy-3-nitropyridin-4-yl)-N,N-dimethylethenamine 
• 160590-36-3 2-methoxy-4-methyl-3-nitropyridine 
• 23056-39-5 2-chloro-3-nitro-4-methylpyridine 
• 152684-30-5 5-bromo-2-methoxy-3-nitropyridine 
• 98-59-9 p-toluenesulfonyl chloride 
• 425380-37-6 4-bromo-7-methoxy-1-hydro-pyrrolo[2,3-c]pyridine 
• 884495-14-1 5-bromo-2-methoxy-4-methyl-3-nitropyridine 

Downstream Products

• 1446232-71-8 N-[3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)phenyl]propane-1-sulfonamide 
• 1446232-72-9 2,2,2-trifluoro-N-[3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)phenyl]ethanesulfonamide 
• 1445992-74-4 ethyl 3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzoate 
• 1445992-76-6 3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzoic acid 
• 1445992-84-6 3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-N-(tetrahydrofuran-2-ylmethyl)benzamide 
• 1446235-06-8 4-[2-(cyclopropylmethoxy)-5-fluorophenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1445993-87-2 4-bromo-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1445993-88-3 4-(2-fluoro-5-nitrophenyl)-6-methyl-1-tosyl-1H-pyrrolo[2,3-c]-pyridin-7(6H)-one 
• 1445993-92-9 ethyl 4-fluoro-3-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzoate 
• 1445992-62-0 6-methyl-4-(2-phenoxyphenyl)-1,6-dihydro-7H-pyrrolo[2,3-c]-pyridin-7-one 
• 1445994-30-8 4-(5-amino-2-(tetrahydro-2H-pyran-4-yloxy)phenyl)-6-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one 
• 1445993-30-5 ethyl 4-(cyclopentylamino)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzoate 
• 1445992-63-1 6-methyl-4-(5-nitro-2-phenoxyphenyl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1445993-86-1 4-bromo-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 

Relevant articles and documents

Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes

According to the binding mode of ABBV-744 with bromodomains and the cape space of HDAC, the novel selective HDAC/BRD4 dual inhibitors were designed and synthesized by the pharmacophore fusion strategy. Evaluating the biomolecular activities through SARs exploration identified three kinds of selective dual inhibitors 41c (HDAC1/BRD4), 43a (pan-HDAC/BRD4) and 43d (HDAC6/BRD4(BD2)), whose target-related cellular activities in MV-4-11 cells were also confirmed. Significantly, the selective dual inhibitor 41c (HDAC1/BRD4) exhibited synergistic effects against MV-4-11 cells, which strongly induced G0/G1 cell cycle arrest and apoptosis, and the first HDAC6/BRD4(BD2) dual inhibitor was found. This study provides support for selective HDAC/BRD4 dual inhibitors as epigenetic probes based on pyrrolopyridone core for the future biological evaluation in different cancer cell lines.

Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain

Bromodomains regulate chromatin remodeling and gene transcription through recognition of acetylated lysines on histones and other proteins. Bromodomain-containing protein TAF1, a subunit of general transcription factor TFIID, initiates preinitiation complex formation and cellular transcription. TAF1 serves as a cofactor for certain oncogenic transcription factors and is implicated in regulating the p53 tumor suppressor. Therefore, TAF1 is a potential target to develop small molecule therapeutics for diseases arising from dysregulated transcription, such as cancer. Here, we report the ATR kinase inhibitor AZD6738 (Ceralasertib) and analogues thereof as bona fide inhibitors of TAF1. Crystallographic and small-angle X-ray scattering studies established that newly identified and previously reported inhibitors stabilize distinct structural states of the TAF1 tandem bromodomain through “open-closed” transitions and dimerization. Combined with functional studies on p53 signaling in cancer cell lines, the data provide new insights into the feasibility and challenges of TAF1 inhibitors as chemical probes and therapeutics.

METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE

The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.